Sequential drug delivery for liver diseases

Huang, Xiaozhong; Lee, Fan; Teng, Yun; Lingam, Corey Bryen; Chen, Zijian; Sun, Min; Song, Ziwei; Balachander, Gowri Manohari; Leo, Hwa Liang; Guo, Qiongyu; Shah, Imran; Yu, Hanry

doi:10.1016/j.addr.2019.11.001

Cited by 9 publications

(3 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to its complex function, liver receives ∼25% of the whole cardiac output despite only constituting 2.5% of total body weight [ 130 , 131 ]. While a massive amount of blood flows to hepatic lobules, hepatocytes are only in contact with conventional therapeutic reagents for a short time (few seconds to minutes) [ 11 ]. These reagents are rapidly metabolized and inactivated by hepatocytes.…”

Section: Advantages Of Nanodrugs For Treatment Of Liver Injurymentioning

confidence: 99%

“…Liver injury is the main factor in pathogenesis of most liver disorders, including hepatitis, acute liver failure, liver fibrosis and liver cancer. Liver disease has a high morbidity rate, with more than 800 million cases reported worldwide (up to 12% of the global population) resulting in about 2 million deaths each year [ 11 , 12 ]. Depending on etiology, liver injury can be classified into injuries caused by exogenous substances (including drug-induced liver injury, alcoholic liver injury, and non-alcoholic fatty liver disease), disease or external stimuli (including COVID-19, viral hepatitis, hepatic ischemia-reperfusion injury (IRI), sepsis, and radiation), and others [ [12] , [13] , [14] , [15] , [16] ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury

Liu

Huang

Zhu

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

Section: Advantages Of Nanodrugs For Treatment Of Liver Injurymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury

Liu

Huang

Zhu

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

“…As a critical metabolic organ, the liver is highly susceptible to the effects of various foreign substances such as exogenous chemicals and small molecule drugs [1, 2]. Hypoglycemic drugs often cause liver damage that disrupts glucose and lipid metabolism [3, 4].…”

Section: Introductionmentioning

confidence: 99%

Canagliflozin Improves Liver Function in Rats by Upregulating Asparagine Synthetase

et al. 2021

View full text Add to dashboard Cite

Introduction: Canagliflozin (CANA) is a sodium-glucose cotransporter 2 inhibitor that was recently approved for treating diabetes. However, its effects on liver function are not well understood. The function of asparagine synthetase (ASNS) has been studied in several cancers but not in liver injury. Therefore, we investigated the connection between CANA and ASNS in alleviating damage (i.e., their hepatoprotective effect) in a rat liver injury model. Methods: The rat model of liver injury was established using carbon tetrachloride treatment. Rats with liver injury were administered CANA orally for 8 weeks daily. After week 8, peripheral blood was collected to measure serum alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase levels. Liver histopathology was examined using hematoxylin and eosin staining to determine the degree of liver injury. Protein expression in the rat livers was examined using Western blotting. Results: CANA treatment decreased serum alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase levels compared with those of the untreated group, demonstrating diminished liver injury. Mechanistically, CANA treatment activated AMP-activated protein kinase (AMPK), leading to increased nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) and activating transcription factor 4 (ATF4), which upregulated ASNS expression in liver-injured rats. Conclusion: CANA significantly alleviated liver injury by activating the AMPK/Nrf2/ATF4 axis and upregulating ASNS expression, indicating its potential for treating patients with type 2 diabetes mellitus with impaired liver function.

show abstract

Machine learning and mechanistic computational modeling of inflammation as tools for designing immunomodulatory biomaterials

Cockrell

Zamora

et al. 2021

Immunomodulatory Biomaterials

View full text Add to dashboard Cite

Sequential drug delivery for liver diseases

Cited by 9 publications

References 161 publications

Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury

Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury

Canagliflozin Improves Liver Function in Rats by Upregulating Asparagine Synthetase

Machine learning and mechanistic computational modeling of inflammation as tools for designing immunomodulatory biomaterials

Contact Info

Product

Resources

About